MiR200-regulated CXCL12β Promotes Fibroblast Heterogeneity and Immunosuppression in Ovarian Cancers

Overview

Journal Nat Commun

Specialty Biology

Date 2018 Mar 15

PMID 29535360

Citations 154

Authors

Anne-Marie Givel

Yann Kieffer

Alix Scholer-Dahirel

Philemon Sirven

Melissa Cardon

Floriane Pelon

Ilaria Magagna

Geraldine Gentric

Ana Costa

Claire Bonneau

Virginie Mieulet

Anne Vincent-Salomon

Fatima Mechta-Grigoriou

Affiliations

Soon will be listed here.

Abstract

High-grade serous ovarian cancers (HGSOC) have been subdivided into molecular subtypes. The mesenchymal HGSOC subgroup, defined by stromal-related gene signatures, is invariably associated with poor patient survival. We demonstrate that stroma exerts a key function in mesenchymal HGSOC. We highlight stromal heterogeneity in HGSOC by identifying four subsets of carcinoma-associated fibroblasts (CAF-S1-4). Mesenchymal HGSOC show high content in CAF-S1 fibroblasts, which exhibit immunosuppressive functions by increasing attraction, survival, and differentiation of CD25FOXP3 T lymphocytes. The beta isoform of the CXCL12 chemokine (CXCL12β) specifically accumulates in the immunosuppressive CAF-S1 subset through a miR-141/200a dependent-mechanism. Moreover, CXCL12β expression in CAF-S1 cells plays a crucial role in CAF-S1 immunosuppressive activity and is a reliable prognosis factor in HGSOC, in contrast to CXCL12α. Thus, our data highlight the differential regulation of the CXCL12α and CXCL12β isoforms in HGSOC, and reveal a CXCL12β-associated stromal heterogeneity and immunosuppressive environment in mesenchymal HGSOC.

Citing Articles

From ductal carcinoma in situ to invasive breast cancer: the prognostic value of the extracellular microenvironment.

Hulahan T, Angel P J Exp Clin Cancer Res. 2024; 43(1):329.

PMID: 39716322 PMC: 11664872. DOI: 10.1186/s13046-024-03236-z.

Molecular and functional profiling of primary normal ovarian cells defines insights into cancer development and drug responses.

Piki E, Dini A, Rantanen F, Bentz F, Paavolainen L, Barker H Mol Ther Oncol. 2024; 32(4):200903.

PMID: 39634630 PMC: 11616607. DOI: 10.1016/j.omton.2024.200903.

Differential activity of MAPK signalling defines fibroblast subtypes in pancreatic cancer.

Veghini L, Pasini D, Fang R, Delfino P, Filippini D, Neander C Nat Commun. 2024; 15(1):10534.

PMID: 39627211 PMC: 11615044. DOI: 10.1038/s41467-024-54975-8.

Integrated analysis of single-cell and bulk transcriptome reveals hypoxia-induced immunosuppressive microenvironment to predict immunotherapy response in high-grade serous ovarian cancer.

Chen Q, Zhang Y, Wang C, Ding H, Chi L Front Pharmacol. 2024; 15:1450751.

PMID: 39605915 PMC: 11598517. DOI: 10.3389/fphar.2024.1450751.

SFRP1 mediates cancer-associated fibroblasts to suppress cancer cell proliferation and migration in head and neck squamous cell carcinoma.

Dong L, Li Y, Song X, Sun C, Song X BMC Cancer. 2024; 24(1):1165.

PMID: 39300373 PMC: 11411997. DOI: 10.1186/s12885-024-12907-1.

References

Zhang L, Conejo-Garcia J, Katsaros D, Gimotty P, Massobrio M, Regnani G . Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003; 348(3):203-13. DOI: 10.1056/NEJMoa020177. View

Konecny G, Wang C, Hamidi H, Winterhoff B, Kalli K, Dering J . Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. J Natl Cancer Inst. 2014; 106(10). PMC: 4271115. DOI: 10.1093/jnci/dju249. View

Xia H, Ng S, Jiang S, Cheung W, Sze J, Bian X . miR-200a-mediated downregulation of ZEB2 and CTNNB1 differentially inhibits nasopharyngeal carcinoma cell growth, migration and invasion. Biochem Biophys Res Commun. 2009; 391(1):535-41. DOI: 10.1016/j.bbrc.2009.11.093. View

Lisanti M, Martinez-Outschoorn U, Sotgia F . Oncogenes induce the cancer-associated fibroblast phenotype: metabolic symbiosis and "fibroblast addiction" are new therapeutic targets for drug discovery. Cell Cycle. 2013; 12(17):2723-32. PMC: 3899185. DOI: 10.4161/cc.25695. View

Ohlund D, Elyada E, Tuveson D . Fibroblast heterogeneity in the cancer wound. J Exp Med. 2014; 211(8):1503-23. PMC: 4113948. DOI: 10.1084/jem.20140692. View

Erez N, Glanz S, Raz Y, Avivi C, Barshack I . Cancer associated fibroblasts express pro-inflammatory factors in human breast and ovarian tumors. Biochem Biophys Res Commun. 2013; 437(3):397-402. DOI: 10.1016/j.bbrc.2013.06.089. View

Toullec A, Gerald D, Despouy G, Bourachot B, Cardon M, Lefort S . Oxidative stress promotes myofibroblast differentiation and tumour spreading. EMBO Mol Med. 2010; 2(6):211-30. PMC: 3377319. DOI: 10.1002/emmm.201000073. View

Tan W, Zhang W, Strasner A, Grivennikov S, Cheng J, Hoffman R . Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature. 2011; 470(7335):548-53. PMC: 3166217. DOI: 10.1038/nature09707. View

Janowski M . Functional diversity of SDF-1 splicing variants. Cell Adh Migr. 2009; 3(3):243-9. PMC: 2712802. DOI: 10.4161/cam.3.3.8260. View

10.

Batista L, Gruosso T, Mechta-Grigoriou F . Ovarian cancer emerging subtypes: role of oxidative stress and fibrosis in tumour development and response to treatment. Int J Biochem Cell Biol. 2013; 45(6):1092-8. DOI: 10.1016/j.biocel.2013.03.001. View

11.

Ko S, Barengo N, Ladanyi A, Lee J, Marini F, Lengyel E . HOXA9 promotes ovarian cancer growth by stimulating cancer-associated fibroblasts. J Clin Invest. 2012; 122(10):3603-17. PMC: 3461910. DOI: 10.1172/JCI62229. View

12.

Huang Z, Shi T, Zhou Q, Shi S, Zhao R, Shi H . miR-141 Regulates colonic leukocytic trafficking by targeting CXCL12β during murine colitis and human Crohn's disease. Gut. 2013; 63(8):1247-57. DOI: 10.1136/gutjnl-2012-304213. View

13.

Lefort S, Thuleau A, Kieffer Y, Sirven P, Bieche I, Marangoni E . CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients. Oncogene. 2016; 36(9):1211-1222. PMC: 5340801. DOI: 10.1038/onc.2016.284. View

14.

Jiang Y, Wu X, Shi B, Wu W, Yin G . Expression of chemokine CXCL12 and its receptor CXCR4 in human epithelial ovarian cancer: an independent prognostic factor for tumor progression. Gynecol Oncol. 2006; 103(1):226-33. DOI: 10.1016/j.ygyno.2006.02.036. View

15.

Parker K, Beury D, Ostrand-Rosenberg S . Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment. Adv Cancer Res. 2015; 128:95-139. PMC: 4662416. DOI: 10.1016/bs.acr.2015.04.002. View

16.

Gil M, Komorowski M, Seshadri M, Rokita H, McGray A, Opyrchal M . CXCL12/CXCR4 blockade by oncolytic virotherapy inhibits ovarian cancer growth by decreasing immunosuppression and targeting cancer-initiating cells. J Immunol. 2014; 193(10):5327-37. PMC: 4225176. DOI: 10.4049/jimmunol.1400201. View

17.

Yang X, Lin Y, Shi Y, Li B, Liu W, Yin W . FAP Promotes Immunosuppression by Cancer-Associated Fibroblasts in the Tumor Microenvironment via STAT3-CCL2 Signaling. Cancer Res. 2016; 76(14):4124-35. DOI: 10.1158/0008-5472.CAN-15-2973. View

18.

Verhaak R, Tamayo P, Yang J, Hubbard D, Zhang H, Creighton C . Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest. 2012; 123(1):517-25. PMC: 3533304. DOI: 10.1172/JCI65833. View

19.

Ruhland M, Loza A, Capietto A, Luo X, Knolhoff B, Flanagan K . Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis. Nat Commun. 2016; 7:11762. PMC: 4899869. DOI: 10.1038/ncomms11762. View

20.

Qiu P, Simonds E, Bendall S, Gibbs Jr K, Bruggner R, Linderman M . Extracting a cellular hierarchy from high-dimensional cytometry data with SPADE. Nat Biotechnol. 2011; 29(10):886-91. PMC: 3196363. DOI: 10.1038/nbt.1991. View